A5073796630- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Metabolism, Diabetes, and Cancer
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Growth Hormone and Insulin-like Growth Factors
- Brain Metastases and Treatment
- Metastasis and carcinoma case studies
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Neuroendocrine Tumor Research Advances
- Cell death mechanisms and regulation
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Reproductive Biology and Fertility
Institut Jules Bordet
2016-2025
Université Libre de Bruxelles
2016-2025
International Breast Cancer Study Group
2016-2021
Frontier Science Foundation
2019
Dana-Farber Cancer Institute
2019
European Institute of Oncology
2019
Frontier Science & Technology Research Foundation
2019
Breast International Group
2018
Institut de Cancérologie de l'Ouest
2016
Institut Gustave Roussy
2009-2014
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Download a PDF Research Summary. We conducted single-group trial in which we evaluated temporary interruption adjuvant young previous cancer. Eligible were 42 years age or younger; had stage I, II, III disease; received for 18 30 months; and desired pregnancy. The primary end point was number events (defined...
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor metastasis pairs: 252 targeted gene sequencing, 152 RNA 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 MEN1 somatic mutations. Metastases were enriched ESR1, PTEN, CDH1, PIK3CA, RB1 mutations; MDM4 MYC amplifications; ARID1A deletions. An increase clonality was...
Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment triple-negative breast cancer (TNBC), therefore, molecular subtyping identification therapeutic pathways are required optimize medical care. The aim present study was define robust TNBC subtypes with clinical relevance. Gene expression profiling by means DNA chips conducted in an internal cohort composed 238 patients. In addition, external data (n = 257), obtained using same chip, were used...
PURPOSE Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction–based next-generation sequencing assay. METHODS Plasma samples (n = 157) from 44 were collected before therapy (baseline), and surgery (presurgery), serially postsurgery including last follow-up sample. The primary end point...
Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact temporary ET interruption to allow pregnancy.POSITIVE enrolled stage I-III HR + cancer, ≤42 years, who had received 18-30 months wished interrupt for pregnancy. Treatment up 2 was permitted pregnancy, delivery breastfeeding, followed by resumption complete...
Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR + mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses counter regulatory T cells (Tregs). Here, we report the efficacy safety of combined programmed cell death protein-1/cytotoxic T-lymphocyte-associated protein 4 blockade concomitant with or after immunomodulatory chemotherapy for HR mBC. Methods Patients mBC starting...
Insulin-like growth factor receptor-1 (IGF-1R) inhibition could be a relevant therapeutic approach in small cell lung cancer (SCLC) given the importance of an IGF-1R autocrine loop and its role DNA damage repair processes. We assessed pAkt protein expression 83 SCLC human specimens. The efficacy R1507 (a monoclonal antibody directed against IGF-1R) alone or combined with cisplatin ionizing radiation (IR) was evaluated H69, H146, H526 cells vitro vivo. Innovative genomic functional approaches...
Abstract Background Preclinical and clinical data suggest that HER2-positive (HER2+) breast cancer (BC) will be amendable to immunotherapeutic approaches. We evaluated pembrolizumab with trastuzumab in patients (pts) trastuzumab-resistant HER2+, PD-L1 positive (PD-L1pos), unresectable loco-regional or metastatic BC a parallel cohort of pts negative (PD-L1neg) during the phase II study. Methods: Pts advanced progression on prior trastuzumab-based therapies, ECOG 0-1, tumor biopsy last year...
Radiotherapy has a critical role in the treatment of small-cell lung cancer (SCLC). The effectiveness radiation SCLC remains limited as resistance results from defects apoptosis. In current study, we investigated whether using Bcl-2/Bcl-XL inhibitor S44563 can enhance radiosensitivity cells vitro and vivo. studies confirmed that caused to acquire hallmarks markedly enhanced sensitivity radiation, determined by clonogenic assay. combination cisplatin-based chemo-radiation showed significant...
Background EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) combination with paclitaxel. Methods HER2-negative BC patients candidates for neoadjuvant chemotherapy were scheduled to receive 12 cycles of weekly EndoTAG-1 22mg/m2 plus paclitaxel 70mg/m2 followed by 3 FEC (Fluorouracil 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2) every weeks surgery. Primary endpoint was percent (%) reduction Magnetic Resonance...
The association between obesity and prognosis in HER2-positive early breast cancer remains unclear, with limited data available. This study aimed to determine the impact of body mass index (BMI) at baseline weight change after 2 years on outcomes patients cancer.ALTTO was a randomized phase III trial cancer. BMI collected randomization after. WHO categories were used: underweight, <18.5 kg/m2; normal weight, 18.5 <25 overweight, ≥25 <30 obese ≥30 kg/m2. A from ≥5.0% ≤5.0% categorized as gain...
Abstract Background: Pregnancy after breast cancer (BC) is of substantial importance for many young women at diagnosis and during follow-up. BC treatment including standard endocrine therapy (ET) (5-10 years) may reduce ovarian reserve the chances subsequent successful pregnancy, given conception contraindicated ET. A temporary interruption ET to attempt carry a pregnancy in this population has never been prospectively studied. Methods: POSITIVE single-arm, prospective,...
<ns4:p>Breast cancer is a global health issue. For decades, breast was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery key genomic driver events involved in carcinogenesis resulted better understanding tumor biology, disease heterogeneity prognosis leading to new modalities targeted therapies opening horizons toward more personalized medicine. In recent years, therapeutic options emerged field metastatic carcinoma,...